Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 1/20 | 0.57 |
| ▸ | EHMT2 | Q96KQ7 | 15/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779098 | 0.96 | EHMT2 (0.55) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3775638 | 0.94 | SSTR5 (0.55) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3776962 | 0.93 | SSTR5 (0.57) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3782743 | 0.92 | SSTR5 (0.57) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3774437 | 0.92 | EHMT2 (0.55) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3782272 | 0.90 | EHMT2 (0.51) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3772515 | 0.90 | EHMT2 (0.53) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3781568 | 0.90 | SSTR5 (0.57) | SSTR5EHMT2KDM1ARCOR1APP | |
| SCHEMBL3781601 | 0.89 | EHMT2 (0.62) | EHMT2KDM1ARCOR1APPTLR7 | |
| SCHEMBL3779221 | 0.88 | EHMT2 (0.54) | SSTR5EHMT2KDM1ARCOR1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2001867-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885EHMT2 4728/4885KDM1A 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.